Personalized CFTR Modulator Therapy for G85E and N1303K Homozygous Patients with Cystic Fibrosis

16Citations
Citations of this article
25Readers
Mendeley users who have this article in their library.

Abstract

CFTR modulator therapy with elexacaftor/tezacaftor/ivacaftor (ETI) has been approved for people with CF and at least one F508del allele in Europe. In the US, the ETI label has been expanded to 177 rare CFTR mutations responsive in Fischer rat thyroid cells, including G85E, but not N1303K. However, knowledge on the effect of ETI on G85E or N1303K CFTR function remains limited. In vitro effects of ETI were measured in primary human nasal epithelial cultures (pHNECs) of a G85E homozygous patient and an N1303K homozygous patient. Effects of ETI therapy in vivo in these patients were assessed using clinical outcomes, including multiple breath washout and lung MRI, and the CFTR biomarkers sweat chloride concentration (SCC), nasal potential difference (NPD) and intestinal current measurement (ICM), before and after initiation of ETI. ETI increased CFTR-mediated chloride transport in G85E/G85E and N1303K/N1303K pHNECs. In the G85E/G85E and the N1303K/N1303K patient, we observed an improvement in lung function, SCC, and CFTR function in the respiratory and rectal epithelium after initiation of ETI. The approach of combining preclinical in vitro testing with subsequent in vivo verification can facilitate access to CFTR modulator therapy and enhance precision medicine for patients carrying rare CFTR mutations.

References Powered by Scopus

Multi-ethnic reference values for spirometry for the 3-95-yr age range: The global lung function 2012 equations

4433Citations
N/AReaders
Get full text

Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele

1438Citations
N/AReaders
Get full text

Cystic fibrosis

1319Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Gathering real-world compassionate data to expand eligibility for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with N1303K or other rare CFTR variants: a viewpoint

17Citations
N/AReaders
Get full text

Cystic fibrosis

14Citations
N/AReaders
Get full text

The expanded French compassionate programme for elexacaftor–tezacaftor–ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study

8Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Graeber, S. Y., Balázs, A., Ziegahn, N., Rubil, T., Vitzthum, C., Piehler, L., … Stahl, M. (2023). Personalized CFTR Modulator Therapy for G85E and N1303K Homozygous Patients with Cystic Fibrosis. International Journal of Molecular Sciences, 24(15). https://doi.org/10.3390/ijms241512365

Readers' Seniority

Tooltip

Researcher 5

71%

PhD / Post grad / Masters / Doc 2

29%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 3

43%

Medicine and Dentistry 2

29%

Pharmacology, Toxicology and Pharmaceut... 1

14%

Neuroscience 1

14%

Article Metrics

Tooltip
Mentions
Blog Mentions: 1

Save time finding and organizing research with Mendeley

Sign up for free